Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Cutera Inc Market Cap
The Cutera Inc (CUTR) share price is expected to increase by 251.32% over the next year. This is based on calculating the average 12-month share price estimate provided by 4 stock analysts who have covered CUTR. Price targets range from $1 at the low end to $5 at the high end. The current analyst consensus for CUTR is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
CUTR is a stock in Health Care which has been forecasted to be worth $2.67 as an average. On the higher end, the forecast price is $5 USD by George Sellers from Stephens & Co. and on the lower end CUTR is forecasted to be $1 by Matt O'Brien from Piper Sandler.
These are the latest 20 analyst ratings of CUTR.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Matt O'Brien Piper Sandler | Neutral | $1 | Reiterates | Aug 9, 2024 |
| George Sellers Stephens & Co. | Overweight | $5 | Maintains | Aug 9, 2024 |
| George Sellers Stephens & Co. | Overweight | $10 | Reiterates | Jun 25, 2024 |
| Matt O'Brien Piper Sandler | Neutral | $3 | Maintains | Jun 21, 2024 |
| Margaret Kaczor William Blair | Market Perform | Upgrade | Mar 22, 2024 | |
| George Sellers Stephens & Co. | Overweight | $10 | Reiterates | Mar 22, 2024 |
| George Sellers Stephens & Co. | Overweight | $10 | Reiterates | Mar 6, 2024 |
| George Sellers Stephens & Co. | Overweight | $10 | Reiterates | Dec 22, 2023 |
| Jonathan Block Stifel | Buy | $10 | Maintains | Nov 9, 2023 |
| Matt O'Brien Piper Sandler | Neutral | $3 | Maintains | Nov 9, 2023 |
| Matt O'Brien Piper Sandler | Neutral | $18 | Upgrade | Jul 27, 2023 |
| Jonathan Block Stifel | Buy | $24 | Maintains | Jul 7, 2023 |
Stephens & Co. | Overweight | Reiterates | Jun 12, 2023 | |
| George Sellers Stephens & Co. | Overweight | $42 | Reiterates | May 16, 2023 |
William Blair | Underperform | Downgrade | May 12, 2023 | |
| Margaret Kaczor William Blair | Underperform | Downgrade | May 11, 2023 | |
| Louise Chen Cantor Fitzgerald | Neutral | $21 | Maintains | May 10, 2023 |
| Matt O'Brien Piper Sandler | Underweight | $14 | Reinstates | May 10, 2023 |
| George Sellers Stephens & Co. | Overweight | $46 | Reiterates | Apr 14, 2023 |
| George Sellers Stephens & Co. | Overweight | $46 | Reiterates | Apr 10, 2023 |
When did it IPO
2004
Staff Count
430
Country
United States
Sector/Industry
Healthcare/Medical Devices
CEO
Mr. Taylor C. Harris
Market Cap
$16.5M
In 2023, CUTR generated $212.4M in revenue, which was a decrease of -15.86% from the previous year. This can be seen as a signal that CUTR's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Sat, 10 Aug 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Cutera, Inc (NASDAQ:CUTR ) Q2 2024 Results Conference Call August 8, 2024 4:30 PM ET Company Participants Shelby Eckerman - Vice President of Finance Taylor Harris - Chief Executive Officer Stuart Drummond - Chief Financial Officer Conference Call Participants Jordan Bernstein - Stifel Harrison Parson - Stephens James Beer - William Blair Operator Thank you for standing by. This is the conference operator.
Thu, 08 Aug 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - BRISBANE, Calif.--(BUSINESS WIRE)--CUTERA, INC. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, today reported financial results for the second quarter ended June 30, 2024. Consolidated revenue for the second quarter of 2024 of $34.4 million Cash, cash equivalents, and restricted cash of $84.3 million AviClear growth of 41% vs prior year period driven by international capital system sales Service growth of 7% vs prior year period, highlighting improvements in field se.
Thu, 08 Aug 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Cutera (CUTR) came out with a quarterly loss of $1.20 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $0.69 per share a year ago.
Wed, 31 Jul 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - BRISBANE, Calif.--(BUSINESS WIRE)--CUTERA, INC. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, and its Japanese subsidiary, Cutera KK, are pleased to announce a strategic partnership with L'Oréal Japan Co. to exclusively promote, market, sell and distribute select SkinCeuticals products to medical and physician-led clinics in Japan. "We are excited about this collaboration with L'Oréal Japan Co. to bring SkinCeuticals' renowned skincare innovations to aesthetic provi.
Fri, 26 Jul 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - BRISBANE, Calif.--(BUSINESS WIRE)--CUTERA, INC. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, announced today that it will report financial results for the second quarter ended June 30, 2024, after the market closes on Thursday, August 8, 2024. The Company's management will host a conference call to discuss these results and related matters at 1:30 p.m. PT (4:30 p.m ET) that same day. Participants can register for the conference call by following registration link.
Mon, 01 Jul 2024
Sentiment - NEUTRAL
Source - InvestorPlace
Summary - Celebrity beauty brand stocks can be exceptionally exciting prospects when first looking at them. After all, they have the endorsement of celebrities to build advertising off of, which tends to get people in the door early on.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
